Functional and structural characterization of an ECF-type ABC transporter for vitamin B12

  1. Joana A Santos
  2. Stephan Rempel
  3. Sandra T M Mous
  4. Cristiane T Pereira
  5. Josy ter Beek
  6. Jan-Willem de Gier
  7. Albert Guskov  Is a corresponding author
  8. Dirk Slotboom  Is a corresponding author
  1. University of Groningen, Netherlands
  2. University of Campinas, Brazil
  3. Stockholm University, Sweden

Abstract

Vitamin B12 (cobalamin) is the most complex B-type vitamin and is synthetized exclusively in a limited number of prokaryotes. Its biologically active variants contain rare organometallic bonds, which are used by enzymes in a variety of central metabolic pathways such as L-methionine synthesis and ribonucleotide reduction. Although its biosynthesis and role as co-factor are well understood, knowledge about uptake of cobalamin by prokaryotic auxotrophs is scarce. Here, we characterize a cobalamin-specific ECF-type ABC transporter from Lactobacillus delbrueckii, ECF-CbrT, and demonstrate that it mediates the specific, ATP-dependent uptake of cobalamin. We solved the crystal structure of ECF-CbrT in an apo conformation to 3.4 Å resolution. Comparison with the ECF transporter for folate (ECF-FolT2) from the same organism, reveals how the identical ECF module adjusts to interact with the different substrate binding proteins FolT2 and CbrT. ECF-CbrT is unrelated to the well-characterized B12 transporter BtuCDF, but their biochemical features indicate functional convergence.

Data availability

Diffraction data have been deposited in PDB under the accession code 6FNP.

The following data sets were generated

Article and author information

Author details

  1. Joana A Santos

    Groningen Biomolecular and Biotechnology Institute (GBB), University of Groningen, Groningen, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8294-3405
  2. Stephan Rempel

    Groningen Biomolecular and Biotechnology Institute (GBB), University of Groningen, Groningen, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  3. Sandra T M Mous

    Groningen Biomolecular and Biotechnology Institute (GBB), University of Groningen, Groningen, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  4. Cristiane T Pereira

    Institute of Biology, University of Campinas, Sao Paulo, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  5. Josy ter Beek

    Groningen Biomolecular and Biotechnology Institute (GBB), University of Groningen, Groningen, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  6. Jan-Willem de Gier

    Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.
  7. Albert Guskov

    Groningen Biomolecular and Biotechnology Institute (GBB), University of Groningen, Groningen, Netherlands
    For correspondence
    a.guskov@rug.nl
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2340-2216
  8. Dirk Slotboom

    Groningen Biomolecular and Biotechnology Institute (GBB), University of Groningen, Groningen, Netherlands
    For correspondence
    d.j.slotboom@rug.nl
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5804-9689

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

  • Josy ter Beek
  • Albert Guskov
  • Dirk Slotboom

European Molecular Biology Organization

  • Joana A Santos
  • Stephan Rempel

Horizon 2020 Framework Programme

  • Dirk Slotboom

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. José D Faraldo-Gómez, National Heart, Lung and Blood Institute, National Institutes of Health, United States

Version history

  1. Received: February 9, 2018
  2. Accepted: May 26, 2018
  3. Accepted Manuscript published: May 29, 2018 (version 1)
  4. Version of Record published: June 12, 2018 (version 2)

Copyright

© 2018, Santos et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,794
    views
  • 434
    downloads
  • 37
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Joana A Santos
  2. Stephan Rempel
  3. Sandra T M Mous
  4. Cristiane T Pereira
  5. Josy ter Beek
  6. Jan-Willem de Gier
  7. Albert Guskov
  8. Dirk Slotboom
(2018)
Functional and structural characterization of an ECF-type ABC transporter for vitamin B12
eLife 7:e35828.
https://doi.org/10.7554/eLife.35828

Share this article

https://doi.org/10.7554/eLife.35828

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Natalia Dolgova, Eva-Maria E Uhlemann ... Oleg Y Dmitriev
    Research Article Updated

    Mediator of ERBB2-driven cell motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many types of cancer and was shown to modulate breast cancer metastasis through altered cell motility. To better understand the function of MEMO1 in cancer cells, we analyzed genetic interactions of MEMO1 using gene essentiality data from 1028 cancer cell lines and found multiple iron-related genes exhibiting genetic relationships with MEMO1. We experimentally confirmed several interactions between MEMO1 and iron-related proteins in living cells, most notably, transferrin receptor 2 (TFR2), mitoferrin-2 (SLC25A28), and the global iron response regulator IRP1 (ACO1). These interactions indicate that cells with high-MEMO1 expression levels are hypersensitive to the disruptions in iron distribution. Our data also indicate that MEMO1 is involved in ferroptosis and is linked to iron supply to mitochondria. We have found that purified MEMO1 binds iron with high affinity under redox conditions mimicking intracellular environment and solved MEMO1 structures in complex with iron and copper. Our work reveals that the iron coordination mode in MEMO1 is very similar to that of iron-containing extradiol dioxygenases, which also display a similar structural fold. We conclude that MEMO1 is an iron-binding protein that modulates iron homeostasis in cancer cells.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Natalia E Ketaren, Fred D Mast ... John D Aitchison
    Research Advance

    To date, all major modes of monoclonal antibody therapy targeting SARS-CoV-2 have lost significant efficacy against the latest circulating variants. As SARS-CoV-2 omicron sublineages account for over 90% of COVID-19 infections, evasion of immune responses generated by vaccination or exposure to previous variants poses a significant challenge. A compelling new therapeutic strategy against SARS-CoV-2 is that of single-domain antibodies, termed nanobodies, which address certain limitations of monoclonal antibodies. Here, we demonstrate that our high-affinity nanobody repertoire, generated against wild-type SARS-CoV-2 spike protein (Mast et al., 2021), remains effective against variants of concern, including omicron BA.4/BA.5; a subset is predicted to counter resistance in emerging XBB and BQ.1.1 sublineages. Furthermore, we reveal the synergistic potential of nanobody cocktails in neutralizing emerging variants. Our study highlights the power of nanobody technology as a versatile therapeutic and diagnostic tool to combat rapidly evolving infectious diseases such as SARS-CoV-2.